A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 304 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... April 22, 2021 Blood test could tailor treatment after surgery July 14, 2021 3D-Printed Surgical Guides Are Helping Surgeons Save More Breast Tissue While... December 2, 2020 New Risk Model Aims to Reduce Breast Cancer Disparities in Black... December 6, 2021 Load more HOT NEWS Can Eating Grilled or Charred Foods Cause Cancer? UK sunburn risk: Third of adults more likely to protect their... Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the... Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges...
